Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels
Publication

Publications

VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels

Title
VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels
Type
Article in International Scientific Journal
Year
2005
Authors
Filho, AL
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Martins, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Costa, SMA
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Fernando Schmitt
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Vol. 201
Pages: 93-99
ISSN: 0344-0338
Publisher: Elsevier
Other information
Authenticus ID: P-000-6D5
Abstract (EN): We examined the immunohistochemical reactivity for vascular endothelial growth factor receptor 3 (VEGFR-3), a protein playing an important role in lymphangiogenesis, in breast cancer. A retrospective series of 77 invasive ductal breast carcinomas was investigated. The relationship between VEGFP-3 expression and clinicopathologic parameters was examined for statistical significance using Pearson's chi-square (x(2)) test and Fisher's exact test (when n < 5). Threshold for significance was p < 0.05. Patient age ranged from 31 to 77 years (mean: 55 years). The VEGFR-3 immunoreactivity was as follows: 5 cases were negative (6.5%)., 35 + (45.4%), 27 + + (35.1%), and 10+++ (13.0%). Reactions were positive for both lymphatic and blood vessels in several cases. VEGFR-3-positive reactions were more frequent in the tumor periphery than within the tumor. Immunoreactivity was also observed in myoepithelial cells surrounding both normal ducts and ducts with ductal carcinoma in situ. Statistical analysis of VEGFR-3 reactions was not significantly related to node status, microvessel density, and tumor grade. Ploidy showed a tendency towards significance (p = 0.063); however, owing to the limited number of cases, statistical significance was not reached. VEGFR-3 lacks lymphatic vessel specificity and is also expressed in blood vessels, myoepithelial cells, and neoplastic cells.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 7
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

UNUSUAL BONY LESIONS OF HISTIOCYTOSIS-X IN A PATIENT PREVIOUSLY TREATED FOR HODGKINS-DISEASE - LETTER TO THE CASE (1990)
Another Publication in an International Scientific Journal
SAMBADE, C; Sobrinho Simoes, M
Unusual bony lesions of histiocytosis X in a patient previously treated for Hodgkin's disease: Comment (1990)
Another Publication in an International Scientific Journal
Sambade, C; Sobrinho Simoes, M
Synovial sarcoma: Immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance (1997)
Another Publication in an International Scientific Journal
Lopes, JM; Bruland, OS; Bjerkehagen, B; Silva, MC; Holm, R; Pettersen, EO; Solheim, OP; SobrinhoSimoes, M; Nesland, JM
Spiradenoma associated with apocrine adenoma component - Critical commentary (1996)
Another Publication in an International Scientific Journal
Lopes, JM
Solitary fibrous tumor of the pleura: Letter to the case II (1991)
Another Publication in an International Scientific Journal
David L; Sobrinho Simoes, M

See all (70)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-18 at 23:08:14 | Privacy Policy | Personal Data Protection Policy | Whistleblowing